Investments

Eli Lilly Retatrutide Phase 3 Results at ADA 2026

Eli Lilly Retatrutide Phase 3 Results at ADA 2026

/ Investments, Stock Market /

Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News Investments Stock Market Breaking Analysis 28.3 Pharma Market Case Study · Witfire Elite View Eli Lilly Retatrutide Phase 3 Results A 28.3% average weight loss at 80 weeks is the headline. But the […]

Eli Lilly Retatrutide Phase 3 Results at ADA 2026 Read More »

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk

/ Investments /

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk | Witfire Elite View Witfire Elite Investment Case Studies Strategy Investment News Investment Witfire Elite View Lilly’s Germany Investment Cut Why Pharma Capital Is Starting to Vote Against Policy Risk Eli Lilly is reportedly halving its planned €2.3 billion Germany investment,

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk Read More »

Scroll to Top